


# ***Vaccines86***



COLD SPRING HARBOR LABORATORY



## **NEW APPROACHES TO IMMUNIZATION**

**DEVELOPING VACCINES AGAINST PARASITIC,  
BACTERIAL, AND VIRAL DISEASES**

# ***Vaccines86***\_\_\_\_\_

## **NEW APPROACHES TO IMMUNIZATION**

**Developing Vaccines against  
Parasitic, Bacterial, and  
Viral Diseases**

Edited by

**Fred Brown**

*Wellcome Biotechnology Ltd.*

**Robert M. Chanock**

*National Institutes of Health*

**Richard A. Lerner**

*Research Institute of Scripps Clinic*



**VACCINES 86**  
**NEW APPROACHES TO IMMUNIZATION**  
**Developing Vaccines against Parasitic,**  
**Bacterial, and Viral Diseases**

© 1986 by Cold Spring Harbor Laboratory

All rights reserved

Printed in the United States of America

Cover design by Emily Harste

*Front cover:* White dots highlight the antigenic sites of poliovirus. A pentamer of the major coat proteins is shown. VP1 is blue, VP2 is yellow, and VP3 is red. (Adapted from J.M. Hogle and D.J. Filman, Research Institute of Scripps Clinic, La Jolla, California, and M. Chow, Massachusetts Institute of Technology, Cambridge.)

*Back cover:* Pasteur injecting the rabies virus vaccine into an early recipient. (Courtesy of the Department of Documentation, Institut Pasteur, Paris, France.)

Library of Congress Cataloging-in-Publication Data

Vaccines 86.





Includes indexes.

1. Vaccines—Congresses. I. Brown, Fred, 1925-  
II. Chanock, Robert M. III. Lerner, Richard A.  
(Richard Alan), 1938- IV. Title: Vaccines eighty-six.  
QR189.V263 1986 615'.372 86-2589  
ISBN 0-87969-190-5 (pbk.)

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cold Spring Harbor Laboratory for libraries and other users registered with the Copyright Clearance Center (CCC) Transactional Reporting Service, provided that the base fee of \$1.00 per article is paid directly to CCC, 27 Congress St., Salem MA 01970. [0-87969-190-5/86 \$1.00 + .00] This consent does not extend to other kinds of copying, such as copying for general distribution, for advertising or promotional purposes, for creating new collective works, or for resale.

All Cold Spring Harbor Laboratory publications may be ordered directly from Cold Spring Harbor Laboratory, Box 100, Cold Spring Harbor, New York 11724. (Phone: 1-800-843-4388) In New York State (516) 367-8425

# ***Vaccines86***\_\_\_\_\_



*First row:* P. Perlmann; E. Norrby, J. Berzofsky  
*Second row:* J. Beale; R. Chanock; C. Langford  
*Third row:* A. Kapikian; H. Greenberg  
*Fourth row:* P. Small; F. Brown, A. Shelekov; R. Lerner

# ***Conference Participants***

- Gordon Ada**, *Department of Microbiology, Australian National University, Canberra, Australia*
- Paul M. Allen**, *Department of Pathology, Washington University School of Medicine, St. Louis, Missouri*
- Carlos Arias**, *Instituto de Investigaciones, Mexico City, Mexico*
- Ralph Arlinghaus**, *Vaccine Development, Johnson & Johnson Biotechnical Center, San Diego, California*
- Jacques W. Armand**, *Institut Merieux, Charbonnieres, France*
- Jit S. Arora**, *Institut Armand-Frappier, Laval, Canada*
- Eduardo Aycardi**, *Vecol, Bogotá, Colombia*
- Barry Baxt**, *Plum Island Animal Disease Center, Greenport, New York*
- A. John Beale**, *Wellcome Research Laboratories, Beckenham, England*
- Judy Beeler**, *National Institutes of Health, Bethesda, Maryland*
- David D. Bennett**, *Veterans Administration Medical Center, Salt Lake City, Utah*
- Jay A. Berzofsky**, *NCI, National Institutes of Health, Bethesda, Maryland*
- James Biddle**, *Johnson & Johnson Biotechnical Center, San Diego, California*
- Mary Helen Binger**, *Department of Molecular Genetics, Hoffmann-La Roche Inc., Nutley, New Jersey*
- James L. Bittle**, *Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, California*
- Bruno Blondel**, *Department of Medical Virology, Institut Pasteur, Paris, France*
- Dani P. Bolognesi**, *Department of Surgery, Duke University Medical Center, Durham, North Carolina*
- Dale E. Bordt**, *Beecham Laboratories, White Hall, Illinois*
- Kathleen Brechaling**, *National Institutes of Health, Bethesda, Maryland*
- Collette Brézin**, *Unité d'Ecologie, Institut Pasteur, Paris, France*
- Fred Brown**, *Wellcome Biotechnology Ltd., Pirbright, England*
- Michael Buchmeier**, *Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California*
- Steven Burakoff**, *Department of Infectious Diseases, Harvard Medical School, Boston, Massachusetts*
- W. Neal Burnette**, *Amgen, Inc., Thousand Oaks, California*
- John J. Cebra**, *Department of Biology, University of Pennsylvania, Philadelphia, Pennsylvania*
- C. Cerini**, *American Cyanamid Co., Pearl River, New York*
- Sekhar Chakrabarti**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Robert M. Chanock**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Kuo-Chi Cheng**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Bruce Chesebro**, *Laboratory of Virus Diseases, Rocky Mountain Laboratories, Hamilton, Montana*
- Lorraine Clarke**, *Houghton Poultry Research Station, Huntingdon, England*
- François Clavel**, *Department of Viral Oncology, Institut Pasteur, Paris, France*

- G.S. Cobon**, *Biotechnology Australia Pty. Ltd., East Roseville, Australia*  
**Jeffrey Cohen**, *National Institutes of Health, Bethesda, Maryland*  
**Sydney Cohen**, *Department of Chemical Pathology, Guys Hospital Medical School, London, England*  
**Peter Collins**, *National Institutes of Health, Bethesda, Maryland*  
**Margaret Conner**, *Department of Virology and Epidemiology, Baylor College of Medicine, Houston, Texas*  
**Kelly Costigan**, *WNET - Channel 13, New York, New York*  
**Paul Cote, Jr.**, *Department of Molecular Virology and Immunology, National Institutes of Health, Rockville, Maryland*  
**Barbara Coupar**, *Department of Microbiology, Australian National University, Canberra, Australia*  
**Brian Crawford**, *Academic Press, Inc., New York, New York*  
**N.B. Cucakovich**, *Ontario, Canada*  
**Beverly Dale**, *California Biotechnology, Inc., Palo Alto, California*  
**Kristian Dalsgaard**, *Plum Island Animal Disease Center, Greenport, New York*  
**Alan R. Davis**, *Wyeth Laboratories Inc., Philadelphia, Pennsylvania*  
**Dan C. DeBorde**, *Department of Epidemiology, University of Michigan, Ann Arbor, Michigan*  
**Michel DeWilde**, *Department of Molecular Genetics, Smith Kline-RIT, Rixensart, Belgium*  
**Francis Delpyroux**, *Department of Genetics, Institut Pasteur, Paris, France*  
**Antonia Destree**, *Applied Biotechnology, Inc., Cambridge, Massachusetts*  
**Dino Dina**, *Chiron Research Laboratories, Emeryville, California*  
**Armen M. Donabedian**, *Department of Epidemiology, University of Michigan, Ann Arbor, Michigan*  
**Barbara Donnell**, *Robert S. First, Inc., White Plains, New York*  
**Friedrich Dörner**, *Department of Microbiology, Immuno AG-Research Center Ortho/Danau, Austria*  
**Gordon R. Dreesman**, *Southwest Foundation for Biomedical Research, San Antonio, Texas*  
**Michael Duchene**, *Department of Molecular Biology, Genzentrum, Martinsried, Federal Republic of Germany*  
**Jane Dyson**, *Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, California*  
**Robert Edelman**, *NIAID, National Institutes of Health, Bethesda, Maryland*  
**Allen Edmundson**, *Department of Biology, University of Utah, Salt Lake City, Utah*  
**Jorg W. Eichberg**, *Southwest Foundation for Biomedical Research, San Antonio, Texas*  
**Emilio A. Emini**, *Department of Virus and Cell Biology, Merck, Sharp & Dohme Research Laboratories, West Point, Virginia*  
**Jay S. Epstein**, *FDA Office of Biologics, Bethesda, Maryland*  
**Joseph H. Esposito**, *Department of Molecular Virology, Centers for Disease Control, Atlanta, Georgia*  
**Anthony Fauci**, *NIAID, National Institutes of Health, Bethesda, Maryland*  
**Morag Ferguson**, *Viral Products, National Institute for Biological Standards and Control, London, England*  
**James G. Files**, *Codon, Brisbane, California*  
**Charles Flexner**, *National Institutes of Health, Bethesda, Maryland*  
**Janette Flint**, *Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California*  
**Jorge Flores**, *National Institutes of Health, Bethesda, Maryland*



- Thomas R. Fuerst**, *National Institutes of Health, Bethesda, Maryland*  
**Robert S. Fujinami**, *Department of Pathology, University of California, San Diego, La Jolla, California*  
**Kalyan Ganguly**, *Department of Molecular Oncology, Hoffmann-La Roche Inc., Nutley, New Jersey*  
**J. Gerber**, *Norden/Smith Kline Co., Lincoln, Nebraska*  
**John L. Gerin**, *Georgetown University, Rockville, Maryland*  
**Richard Giles**, *Advanced Genetics Research Institute, Oakland, California*  
**Roger Glass**, *National Institutes of Health, Bethesda, Maryland*  
**Fred Golini**, *Syntro Corp., San Diego, California*  
**Antonio Gonzalez**, *Department of Molecular Biology, Universidad Autonoma, Madrid, Spain*  
**Michael Goode**, *National Institutes of Health, Bethesda, Maryland*  
**Mario Gorziglia**, *National Institutes of Health, Bethesda, Maryland*  
**E.A. Gould**, *London School of Hygiene and Tropical Medicine, Arbovirus Research Unit, St. Albans, England*  
**Harry Greenberg**, *Palo Alto Veterans Administration Hospital, Palo Alto, California*  
**Marvin Grubman**, *Plum Island Animal Disease Center, Greenport, New York*  
**Beatrice Hahn**, *Department of Hematology and Oncology, University of Alabama, Birmingham, Alabama*  
**Thomas Hale**, *Walter Reed Army Medical Center, Washington, D.C.*  
**Shirley Halling**, *Molecular Genetics, Inc., Minnetonka, Minnesota*  
**T.J.R. Harris**, *Celltech Ltd., Slough, England*  
**Ellen Heber-Katz**, *Wistar Institute, Philadelphia, Pennsylvania*  
**Fred Heffron**, *Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, California*  
**Franz X. Heinz**, *Institute of Virology, University of Vienna, Vienna, Austria*  
**Richard Hesse**, *Schering Corp., Elkhorn, Nebraska*  
**W.G. Hesselink**, *Intervet International B.V., Boxmeer, The Netherlands*  
**Joachim Hilfenhaus**, *Behringwerke, Marburg, Federal Republic of Germany*  
**Richard Hjorth**, *Wyeth Laboratories, Philadelphia, Pennsylvania*  
**Wayne T Hockmeyer**, *Department of Immunology, Walter Reed Army Institute of Research, Washington, D.C.*  
**James M. Hogle**, *Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, California*  
**Yasutak Hoshino**, *National Institutes of Health, Bethesda, Maryland*  
**Richard Houghten**, *Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, California*  
**Jih-Han Hsieh**, *Development Center for Biotechnology, Taipei, Taiwan, Republic of China*  
**Nien-Tai Hu**, *National Chung Hsing University, Taiwan, Republic of China*  
**Shiu-Lok Hu**, *Oncogen Inc., Seattle, Washington*  
**Daral J. Jackwood**, *Battelle/Columbus Laboratory, Columbus, Ohio*  
**Peter Jahrling**, *United States Army Medical Research Institute of Infectious Diseases, Ft. Detrick, Frederick, Maryland*  
**Keith Jensen**, *Pfizer Central Research, Groton, Connecticut*  
**Jeffrey M. Johnston**, *Department of Molecular Biology, University of Utah School of Medicine, Salt Lake City, Utah*  
**Michael Johnstone**, *International Health and Biomedicine, East Sussex, England*  
**Wolfgang K. Joklik**, *Department of Microbiology and Immunology, Duke University Medical Center, Durham, North Carolina*  
**Dominic Justewicz**, *Department of Virology, Institut Armand-Frappier, Laval, Canada*



- Shahjahan Kabir**, *International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh*
- Donald Kahn**, *Biological Research, Pitman Moore, Inc., Washington Crossing, New Jersey*
- A.D. Kanarek**, *Willondale, Ontario, Canada*
- Patrick Kanda**, *Southwest Foundation for Biomedical Research, San Antonio, Texas*
- Albert Z. Kapikian**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Ruth Karron**, *National Institutes of Health, Bethesda, Maryland*
- Julius Kasel**, *Department of Microbiology, Baylor College of Medicine, Houston, Texas*
- Jonathan Katz**, *Department of Virology, National Veterinary Services Laboratories, Ames, Iowa*
- Joseph Kendall**, *Plum Island Animal Disease Center, Greenport, New York*
- Ronald C. Kennedy**, *Southwest Foundation for Biomedical Research, San Antonio, Texas*
- Stephen B.H. Kent**, *Department of Biology, California Institute of Technology, Pasadena, California*
- I.J.A.R. Keus**, *Duphar B.V., Weesp, The Netherlands*
- Marie-Paule Kieny**, *Transgene S.A., Strasbourg, France*
- James C. King**, *Vanderbilt University, Nashville, Tennessee*
- Abram Kirschenbaum**, *Research Science Development Unit, New York, New York*
- Frank Klotz**, *NIAID National Institutes of Health, Bethesda, Maryland*
- William Knudtson**, *National Veterinary Services Laboratory, Ames, Iowa*
- Thomas A. Kost**, *Norden Laboratories, Lincoln, Nebraska*
- Debra Kotloff**, *Department of Biology, University of Pennsylvania, Philadelphia*
- Girish Kotwal**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Nirbhay Kumar**, *NIAID National Institutes of Health, Bethesda, Maryland*
- Hans Kupper**, *Behringwerke AG, Marburg, Federal Republic of Germany*
- Ching-Juh Lai**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Christopher Langford**, *Medical Research, Royal Melbourne Hospital, Victoria, Australia*
- Sally S.G. Lee**, *Department of Molecular Biology, Wyeth Laboratories, Philadelphia, Pennsylvania*
- Stanley Lemon**, *University of North Carolina, Chapel Hill, North Carolina*
- Richard A. Lerner**, *Research Institute of Scripps Clinic, La Jolla, California*
- Mark Levner**, *Wyeth Laboratories, Philadelphia, Pennsylvania*
- Keith Limbach**, *New York State Department of Health, Albany, New York*
- Jung-Yaw Lin**, *Taipei, Taiwan, Republic of China*
- Susana Lopez**, *Instituto de Investigaciones Biomedicas, Mexico City, Mexico*
- Paul A. Luciw**, *Chiron Corp., Emeryville, California*
- William MacConnell**, *Syntro Corp., San Diego, California*
- Michael Mackett**, *Department of Molecular Biology, Christie Hospital, Manchester, England*
- Yoshihiro Makino**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Carmine Marchioli**, *The Upjohn Co., Kalamazoo, Michigan*
- Lewis J. Markoff**, *National Institutes of Health, Bethesda, Maryland*
- Malcolm Martin**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Duncan Maskell**, *Department of Bacterial Genetics, Wellcome Research Laboratories, Beckenham, England*
- Tom J. Mason**, *Department of Molecular Immunology, Commonwealth Serum Laboratories, Parkville, Australia*
- Gail Mazzara**, *Applied Biotechnology, Inc., Cambridge, Massachusetts*
- Stephen McAndrew**, *Hoffmann-La Roche Inc., Nutley, New Jersey*

- Donald McCarthy**, *Department of Biological Research, Pitman Moore, Inc., Washington Crossing, New Jersey*
- Joan McMahan**, *M&N Consultants, Boyton Beach, Florida*
- Marie L. Michel**, *Department of Genetics, Institut Pasteur, Paris, France*
- C. Mickiewicz**, *American Cyanamid Co., New York, New York*
- David R. Milich**, *Research Institute of Scripps Clinic, La Jolla, California*
- Louis Miller**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Percy Minden**, *Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, California*
- Douglas Moore**, *Plum Island Animal Disease Center, Greenport, New York*
- Andrew Morgan**, *University of Chicago, Chicago, Illinois*
- Donald P. Morgan**, *Plum Island Animal Disease Center, Greenport, New York*
- Manfred Motz**, *Max von Pettenkofer Institute, Munich, Federal Republic of Germany*
- Robert Naso**, *Johnson & Johnson Biotechnology Center, San Diego, California*
- A. Robert Neurath**, *The New York Blood Center, New York, New York*
- Gary Noble**, *Center for Disease Control, Atlanta, Georgia*
- Jack Nunberg**, *Cetus Corp., Emeryville, California*
- Ruth S. Nussenzweig**, *Department of Molecular Parasitology, New York University Medical Center, New York, New York*
- Victor Nussenzweig**, *Department of Pathology, New York University Medical Center, New York, New York*
- Kate Nyman**, *National Public Health Institute, Helsinki, Finland*
- Peter O'Hanley**, *Department of Medicine, Stanford Medical School, Stanford, California*
- Paul A. Offit**, *Department of Gastroenterology, Veterans Administration Medical Center, Palo Alto, California*
- Michael B.A. Oldstone**, *Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California*
- Robert Olmsted**, *National Institutes of Health, Bethesda, Maryland*
- Elizabeth J. Ouldrige**, *Wellcome Biotechnology Ltd., Pirbright, England*
- Shozo Ozaki**, *Institut Pasteur, Paris, France*
- Dennis Panicali**, *Applied Biotechnology, Inc., Cambridge, Massachusetts*
- Chia C. Pao**, *Department of Biochemistry, Chang Gung Medical College, Taoyuan, Taiwan, Republic of China*
- Enzo Paoletti**, *New York State Department of Health, Albany, New York*
- Peter R. Paradiso**, *Praxis Biologics, Inc., Rochester, New York*
- Manuel E. Patarroyo**, *Department of Immunology, Hospital San Juan de Dios, Bogotá, Colombia*
- Margaret Perkins**, *Rockefeller University, New York, New York*
- Marion Perkus**, *New York State Department of Health, Albany, New York*
- Peter Perlmann**, *Department of Immunology, University of Stockholm, Sweden*
- Eberhard Pfaff**, *Department of Microbiology, University of Heidelberg, Heidelberg, Federal Republic of Germany*
- Antonia Piccini**, *New York State Department of Health, Albany, New York*
- Christopher Pohl**, *Department of Molecular Virology and Immunology, Georgetown University, Rockville, Maryland*
- Helmut Pohlitz**, *Frankfurt, Federal Republic of Germany*
- W.P.A. Posthumus**, *Central Veterinary Institute, Lelystad, The Netherlands*
- Alfred M. Prince**, *New York Blood Center, New York, New York*
- Gregory Prince**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Anthony Purchio**, *Oncogene Inc., Seattle, Washington*
- Marie-J. Quentin-Millet**, *Institut Merieux, Charbonniers, France*

- Ranjan Ramasamy**, *Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California*
- Ruth Rappaport**, *Wyeth Laboratories, Philadelphia, Pennsylvania*
- George N. Reeke, Jr.**, *Rockefeller University, New York, New York*
- Peter Reeve**, *Smith Kline Beckman, Swedeland, Pennsylvania*
- Jakob Reiser**, *Swiss Serum and Vaccine Institute, Berne, Switzerland*
- John M. Rice**, *Battelle-Columbus Laboratories, Columbus, Ohio*
- Sandra Ristow**, *Department of Veterinary Microbiology and Pathology, Washington State University, Pullman, Washington*
- David J. Rowlands**, *Wellcome Biotechnology, Ltd, Pirbright, England*
- Tineke Rutgers**, *Smith Kline-RIT, Rixensart, Belgium*
- Mark Rweyemamu**, *Pfizer S.A., San Paulo, Brazil*
- Gertrude Schloer**, *Plum Island Animal Disease Center, Greenport, New York*
- Jill Schneider**, *Lederle Laboratories, Pearl River, New York*
- George Shaw**, *Department of Hematology and Oncology, University of Alabama, Birmingham, Alabama*
- Alexis Shelokov**, *Government Services Division, Salk Institute, Columbia, Maryland*
- S.-H. Shen**, *Connaught Research Institute, Willowdale, Canada*
- K. Shimizu**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Parker Small, Jr.**, *University of Florida College of Medicine, Gainesville, Florida*
- Robert Smith**, *Abbott Laboratories, Abbott Park, Illinois*
- Mark Snyder**, *National Institutes of Health, Bethesda, Maryland*
- Peter J. Southern**, *Department of Immunology, Research Institute of Scripps Clinic, La Jolla, California*
- Melanie Spriggs**, *National Institutes of Health, Bethesda, Maryland*
- James W. Stave**, *Plum Island Animal Disease Center, Greenport, New York*
- Ralph Steinman**, *Rockefeller University, New York, New York*
- Vernon C. Stevens**, *Department of Obstetrics and Gynecology, Ohio State University, Columbus, Ohio*
- Monica Stewart**, *Beatson Institute for Cancer Research, Glasgow, Scotland*
- Howard Streicher**, *NCI, National Institutes of Health, Bethesda, Maryland*
- Michael Sulzinski**, *Lederle Laboratories, Pearl River, New York*
- Michael Sveda**, *Genex Corp., Gaithersburg, Maryland*
- Steve Swanson**, *Lederle Laboratories, Pearl River, New York*
- Pierre Talbot**, *Department of Virology, Institut Armand-Frappier, Laval, Canada*
- James Tartaglia**, *New York State Department of Health, Albany, New York*
- Andre Tartar**, *Faculté de Pharmacie, Lille, France*
- Jill Taylor**, *Queensland Institute of Medical Research, Brisbane, Australia*
- Pallaih Thammana**, *American Cyanamid Co., Princeton, New Jersey*
- George Thornton**, *Johnson & Johnson, San Diego, California*
- James G. Timmins**, *Molecular Biology, The Upjohn Company, Kalamazoo, Michigan*
- Pierre Tiollais**, *Department of Genetics, Institut Pasteur, Paris, France*
- F.M. Tomley**, *Houghton Poultry Research Station, Huntingdon, England*
- William C. Topp**, *American Cyanamid Co., Princeton, New Jersey*
- Michael Trundel**, *Department of Virology, Institut Armand-Frappier, Laval, Canada*
- Franklin Tyeryar**, *NIAID, National Institutes of Health, Bethesda, Maryland*
- Tito Ubertini**, *Lederle Laboratories, Pearl River, New York*
- Mats Wahlgren**, *Department of Immunology, University of Stockholm, Stockholm, Sweden*
- Simon Wain-Hobson**, *Department of Genetics, Institut Pasteur, Paris, France*
- Thomas Waldmann**, *NCI, National Institutes of Health, Bethesda, Maryland*
- G.T. Wang**, *American Cyanamid Co., Princeton, New Jersey*

**Audrey Wanger**, *New York State College of Veterinary Medicine, Ithaca, New York*  
**Kenneth Warren**, *Rockefeller Foundation, New York, New York*  
**Michael Wathen**, *The Upjohn Co., Kalamazoo, Michigan*  
**Ronald Wegrzyn**, *Smith Kline Beckman, Swedeland, Pennsylvania*  
**Wicher J. Weijer**, *Department of Microbiology, University of Groningen, Groningen, The Netherlands*  
**Manfred Weitz**, *National Institutes of Health, Bethesda, Maryland*  
**Roy Widdus**, *International Health, National Academy of Sciences, Washington, D.C.*  
**Ian A. Wilson**, *Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, California*  
**Paul Wingfield**, *Biogen S.A., Geneva, Switzerland*  
**Michael D. Winther**, *Wellcome Biotechnology Ltd., Beckenham, England*  
**M.H. Wishner**, *Houghton Poultry Research Station, Huntingdon, England*  
**Judith Wolcott**, *The Upjohn Co., Kalamazoo, Michigan*  
**Henry Wolfe**, *E.I. du Pont de Nemours & Co., Wilmington, Delaware*  
**Peter Wright**, *Department of Molecular Biology, Research Institute of Scripps Clinic, La Jolla, California*  
**Stephen Wright**, *University of Utah, Salt Lake City, Utah*  
**Da-Ping Yang**, *Wyeth Laboratories, Philadelphia, Pennsylvania*  
**James Young**, *Smith Kline Beckman, Swedeland, Pennsylvania*  
**Scott Zamvil**, *Department of Neurology, Stanford University, Stanford, California*  
**Charles Zarley**, *Battelle/Columbus Laboratories, Columbus, Ohio*  
**Bangti Zhao**, *National Institutes of Health, Bethesda, Maryland*



F. MacFarlane Burnet  
(1899-1985)



John F. Enders  
(1897-1985)



Rodney R. Porter  
(1917-1985)

# ***Preface***

The highly successful meetings held at Cold Spring Harbor Laboratory in 1983 and 1984 on Modern Approaches to Vaccines underscored the interest in this topic, and judging from the increase in the number of participants at the meeting in 1985, there appears to be no waning of this interest. As in the previous volumes, *Vaccines 86* includes papers on viruses, pathogenic bacteria, and parasites that cause important diseases. There are, however, two important additions to this volume. A complete section is devoted to a single disease, AIDS. With one of the greatest microbiological problems confronting us at this time, it was considered opportune to discuss fully the prospects for a vaccine against this disease. A section on immunology is also included because we recognize that in order to achieve optimal effectiveness of the new vaccines, we must reach a better understanding of the immunological responses that provide maximal resistance to infection and disease.

The meeting was held within 2 weeks of the deaths of three Nobel laureates, F. MacFarlane Burnet, John F. Enders, and Rodney R. Porter, whose contributions to the fields of virology and immunology laid the foundations of much of the work described here. We dedicate this volume to their memory.

The organizers wish to thank the NIH-NIAID Intramural Research Program and Wellcome Biotechnology, Ltd., for their generous financial support. We also acknowledge the contributions from the following Corporate Sponsors, who provided core support for this meeting: Agrigenetics Corporation, American Cyanamid Company, Amersham International plc, Becton Dickinson and Company, Biogen S.A., Cetus Corporation, Ciba-Geigy Corporation, CPC International Inc., E.I. du Pont de Nemours & Company, Genentech, Inc., Genetics Institute, Hoffmann-La Roche Inc., Johnson & Johnson, Eli Lilly and Company, Mitsui Toatsu Chemicals, Inc., Monsanto Company, Pall Corporation, Pfizer Inc., Schering-Plough Corporation, Smith Kline & French Laboratories, and the Upjohn Company.

Once again, we thank Dr. James Watson for his continuing support and for making available the conference and publications facilities of Cold Spring Harbor Laboratory. The meetings office staff, headed by Gladys Kist, provided invaluable assistance and we thank them for their help in organizing the meeting. We also appreciate the efforts of the publications office, in particular Nancy Ford, Dorothy Brown, and Marty McMaster, for helping to prepare this book for publication. Not least, the efficiency of Herb Parsons in helping all the speakers at the meeting to communicate their data to the participants is greatly appreciated.

F.B.  
R.M.C.  
R.A.L.

# Contents

Conference Participants, v

Preface, xiii

## Structural and Chemical Aspects of Antigen-Antibody Union

Thoughts on the Occasion of the Solution of the Three-dimensional Structure of Poliovirus <i>Erling Norrby</i>	1
High-resolution Structure of Poliovirus: Three-dimensional Distribution of Antigenic Sites in the Intact Virion <i>James M. Hogle, David J. Filman, and Marie Chow</i>	3
Antipeptide Antibodies and the Disorder-Order Phenomenon <i>Peter E. Wright, H. Jane Dyson, Mark Rance, John Ostresh, Richard A. Houghten, Ian A. Wilson, and Richard A. Lerner</i>	15
Relative Importance of Position and Individual Amino Acid Residues in Peptide Antigen-Antibody Interactions: Implications in the Mechanism of Antigenic Drift and Antigenic Shift <i>Richard A. Houghten, Sarah R. Hoffmann, and Henry L. Niman</i>	21
Three-dimensional Structure of $\beta_2$ -Microglobulin: Its Relationships to Immunoglobulins and the Class I Major Histocompatibility Antigens <i>George N. Reeke, Jr. and Joseph W. Becker</i>	27
Structural Analysis of Antipeptide Antibodies against Influenza Virus Hemagglutinin <i>Ian A. Wilson, Katherine F. Bergmann, and Enrico A. Stura</i>	33
A Synthetic Peptide Vaccine against Human Chorionic Gonadotropin <i>Vernon C. Stevens</i>	39
Comparison of the Structures of the Major Antigenic Sites of Foot-and-Mouth Disease Viruses of Two Different Serotypes <i>Elizabeth J. Ouldrige, Nigel R. Parry, Paul V. Barnett, Christopher Bolwell, David J. Rowlands, Fred Brown, James L. Bittle, Richard A. Houghten, and Richard A. Lerner</i>	45
Foot-and-Mouth Disease Virus Variants with Broad and Narrow Antigenic Spectra <i>Christopher Bolwell, Nigel R. Parry, David J. Rowlands, Fred Brown, and Elizabeth J. Ouldrige</i>	51
Three-dimensional Analyses of the Binding of Chemotactic and Opioid Peptides to the Mcg Light-chain Dimer <i>Allen B. Edmundson, Kathryn R. Ely, and James N. Herron</i>	57



<b>Specific Long-term Protection from a Lethal HSV Infection in the Absence of a Detectable Antibody Response</b>	65
<i>Ellen Heber-Katz, Eiji Watari, and Bernhard Dietzschold</i>	
<b>Evaluation and Application of Methods for the Prediction of Antigenic Regions in Proteins</b>	71
<i>Wicher J. Weijer, Gjalte W. Welling, and Sytske Welling-Wester</i>	
<b>Bacterial Fusion Proteins as Immunogens</b>	79
<i>Michael D. Winther, Robert H. Bomford, Geoffrey Allen, and Fred Brown</i>	
<b>Anti-Idiotypic Antibodies as a Potential Vaccine against Hepatitis-B Virus</b>	85
<i>Ronald C. Kennedy, Jorg W. Eichberg, and Gordon R. Dreesman</i>	
<b>Studies on Foot-and-Mouth Disease Virus Neutralization</b>	91
<i>Eberhard Pfaff, Ewald Beck, Christa Kuhn, Heinz Schaller, Hans-Jürgen Thiel, Karl Strohmaier, and Johann Leban</i>	
<b>Diversity of the Antibody Response</b>	97
<i>Thomas J. Mason, Stuart J. Rodda, and H. Mario Geysen</i>	
 <b>Antigen Presentation and Processing</b>	
<b>Antigen Presentation and Enhancement of Immunity: An Introduction</b>	105
<i>Gordon L. Ada</i>	
<b>Molecular Events in Antigen Processing and Presentation</b>	109
<i>Paul M. Allen, Bruce P. Babbitt, Emil R. Unanue, Gary R. Matsueda, and Edgar Haber</i>	
<b>Development of Antibody Responses in Tissue Culture: Functions of Antigen-presenting Cells</b>	113
<i>Kayo Inaba and Ralph Steinman</i>	
<b>Reconstituted Membranes and Liposomes in the Induction of the Cytolytic T Lymphocyte Response</b>	119
<i>Steven J. Burakoff, Julia L. Greenstein, Ofra Weinberger, and Steven H. Herrmann</i>	
<b>Structural and Conformational Requirements for Protein Antigen Recognition by MHC Class-II-restricted T Cells and Clones</b>	123
<i>Jay A. Berzofsky, Ira J. Berkower, Kemp B. Cease, Gail K. Buckenmeyer, Howard Z. Streicher, and Charles DeLisi</i>	
<b>Effective Gut Mucosal Stimulation of IgA-committed B Cells by Antigen</b>	129
<i>John J. Cebra, Juliet A. Fuhrman, Deborah A. Leberman, and Steven D. London</i>	
 <b>Malaria</b>	
<b>Recent Efforts in the Development of a Sporozoite Malaria Vaccine against <i>Plasmodium falciparum</i></b>	135
<i>Wayne T. Hockmeyer, W. Ripley Ballou, and James F. Young</i>	

<b>Analysis of Molecular Interactions and Epitopes in the Target Antigens of Transmission-blocking Immunity in Malaria</b>	139
<i>Nirbhay Kumar and Richard Carter</i>	
<b>Antigens of the Asexual Blood Stages of <i>Plasmodium falciparum</i> and Their Expression in Recombinant Vaccinia Virus</b>	145
<i>Christopher J. Langford, David J. Kemp, Robin F. Anders, Graham F. Mitchell, Stirling J. Edwards, Geoffrey L. Smith, and Bernard Moss</i>	
<b>Specificity and Inhibitory Activity of Antibodies to a <i>Plasmodium falciparum</i> Antigen (Pf 155) and Its Major Amino Acid Repeat Sequence</b>	149
<i>Peter Perlmann, Klavs Berzins, Jan Carlsson, Hedvig Perlmann, Katarina Sjöberg, Marita Troye-Blomberg, Rachanee Udomsangpetch, Mats Wahlgren, Birgitta Wåhlin, Anders Björkman, Elkin M. Patarroyo, and Hans Wigzell</i>	
<b>Interaction of <i>Plasmodium falciparum</i> Merozoite Proteins with the Erythrocyte Surface</b>	157
<i>Margaret E. Perkins and Jeffrey V. Ravetch</i>	
<b>Effect of Immunity to the 140-kD Merozoite Protein on Antigen Expression in Chronic <i>Plasmodium knowlesi</i> Malaria Infection</b>	161
<i>Francis W. Klotz, Diana E. Hudson, and Louis H. Miller</i>	
<b>Expression of Malaria Circumsporozoite Protein and Hepatitis-B Virus Surface Antigen by Infectious Vaccinia Virus</b>	165
<i>Kuo-Chi Cheng, Geoffrey L. Smith, Bernard Moss, Fidel Zavala, Ruth Nussenzweig, and Victor Nussenzweig</i>	
<b>Serological Cross-reactions between Genetically Distinct <i>Plasmodium falciparum</i> Antigens</b>	169
<i>Mats Wahlgren, Lena Åslund, Lena Franzén, Mats Sundvall, Klavs Berzins, Birgitta Wåhlin, Wipaporn Ruangjirachuporn, Rachanee Udomsangpetch, Hedvig Perlmann, Anders Björkman, Hans Wigzell, Ulf Petterson, Peter Perlmann, Odile Mercereau-Puijalon, and Denise Mattei</i>	
<b>A Merozoite Surface Antigen of <i>Plasmodium falciparum</i> Cloned and Expressed in <i>Escherichia coli</i></b>	175
<i>Janette E. Flint, Feroza Ardeshir, and Robert T. Reese</i>	
 <b>Bacterial Vaccines</b>	
<b>Immune Response to <i>Shigella</i> Infections and to <i>Shigella</i> Vaccines</b>	181
<i>Thomas Larry Hale, Edwin V. Oaks, Samuel B. Formal, Gabriel Dinari, and Peter Echeverria</i>	
<b>Molecular Analysis of Pertussis Vaccine Encephalopathy</b>	187
<i>Lawrence Steinman, Alison Weiss, Nancy Adelman, Mae Lim, Richard Zuniga, John Oehlert, Eric Hewlett, Stanley Falkow, and Scott Zamvil</i>	
<b>Importance of Gal-Gal Binding in the Pathogenesis of <i>Escherichia coli</i> Pyelonephritis: A Gal-Gal Pilus Vaccine Prevents Pyelonephritis in BALB/c Mice</b>	191
<i>Peter O'Hanley, M. Alexander Schmidt, David Lark, and Gary Schoolnik</i>	